{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.11","upperLimit":"12.06","value":"10.38"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"}],"units":"Participants"}],"description":"Time from first bb2121 infusion to first documentation of progressive disease (PD), or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"BB2121","id":"OG000","title":"BB2121"}],"paramType":"MEDIAN","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"From first dose to 24 months after first dose","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"Months"}